Open Access. Powered by Scholars. Published by Universities.®

Arts and Humanities Commons

Open Access. Powered by Scholars. Published by Universities.®

External Link

1995

Research Subjects

Articles 1 - 3 of 3

Full-Text Articles in Arts and Humanities

Cruel And Unusual Treatment, Carl Elliott, Charles Weijer Nov 1995

Cruel And Unusual Treatment, Carl Elliott, Charles Weijer

Charles Weijer

No abstract provided.


Characterizing The Population In Clinical Trials: Barriers, Comparability, And Implications For Review, Charles Weijer Jun 1995

Characterizing The Population In Clinical Trials: Barriers, Comparability, And Implications For Review, Charles Weijer

Charles Weijer

The definition of the study population for a clinical trial via the criteria for trial eligibility has implications for the validity of the study and its applicability to clinical practice. Though issues of equity regarding the selection of subjects for research have long been a concern of ethicists, issues regarding the impact of subject selection on a trial's generalizability have only recently attracted ethical scrutiny. After a review of the history of the ethics of subject selection, I focus on three empirical questions regarding the generalizability of clinical trials. (1) What proportion of diseased populations are studied in clinical trials? …


The Breast Cancer Research Scandal: Addressing The Issues, Charles Weijer Apr 1995

The Breast Cancer Research Scandal: Addressing The Issues, Charles Weijer

Charles Weijer

The three claims put forward by Dr. Roger Poisson to rationalize his enrollment of ineligible subjects in clinical trials do not justify research fraud. None the less, certain lessons for the conduct of clinical research can be learned from the affair: experimental therapies should be made available to technically ineligible subjects when no effective therapy exists for their disease; further research must investigate the possible benefits of clinical-trial participation; broadly based, pragmatic trials must be regarded as the ideal model; and each eligibility criterion in a clinical-trial protocol should be justified.